title: Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer.
abstract: This study is a retrospective analysis evaluating the efficacy and toxicity of combination chemotherapy with S-1 and oxaliplatin (SOX) as first-line treatment in elderly patients with advanced gastric cancer. One hundred and twenty-nine patients with recurrent or metastatic gastric adenocarcinoma were treated with SOX; S-1 (40-60 mg depending on patient's body surface area) was given orally, twice daily on days 1 to 14 followed by a 7-day rest period, 130 mg/m(2) oxaliplatin was given as an intravenous infusion over 2-hours on day one. The cycle was repeated every three weeks. All of the patients were older than 65 years. Among 129 patients enrolled, nine patients could not be evaluated for responses because of the absence of any measurable lesions or early discontinuation of therapy. Assessment of the response of 120 patients was made. The overall objective response rate was 54.2 % (95 %CI, 45.3-63.1 %), with three complete responses and 62 partial responses. The disease control rate was 80.8 % (95 %CI, 73.8-87.8 %). The median follow-up period was 23 months (range, 5-42 months). The median time to progression was 6.9 months (95 %CI, 5.5-8.3 months) and the median overall survival was 12.8 months (95 %CI, 11.4-14.2 months). The one-year survival rate was 57.5 % (95 %CI, 48.7-66.3 %). In 129 patients assessed safety, grade 3 and 4 toxicities included leucopenia (20.9 %), neutropenia (24.0 %), anemia (10.9 %), thrombocytopenia (10.1 %), anorexia (3.1 %), peripheral neurotoxicity (15.5 %), and fatigue (12.4 %). No treatment-related deaths occurred. Combination chemotherapy with SOX offers an effective, safe and well-tolerated regimen for elderly patients with advanced gastric cancer.
authors: Department of Medical Oncology, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Fuzhou, 350001, Fujian, People's Republic of China.
authors: Dong-ta
authors: DT
authors: Zhong
authors: Ri-ping
authors: RP
authors: Wu
authors: Xin-li
authors: XL
authors: Wang
authors: Xiao-bing
authors: XB
authors: Huang
authors: Meng-xin
authors: MX
authors: Lin
authors: Yan-qin
authors: YQ
authors: Lan
authors: Qiang
authors: Q
authors: Chen
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010094:Oxonic Acid / Q000008:administration & dosage; D011379:Prognosis; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid
references: Ann Oncol. 2010 May;21(5):1001-5
references: 19875759
references: J Clin Oncol. 2006 Nov 1;24(31):4991-7
references: 17075117
references: N Engl J Med. 2008 Jan 3;358(1):36-46
references: 18172173
references: ANZ J Surg. 2006 Jun;76(6):458-61
references: 16768768
references: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references: 19474385
references: Lancet Oncol. 2008 Mar;9(3):215-21
references: 18282805
references: Cancer Chemother Pharmacol. 2010 Feb;65(3):473-80
references: 19551382
references: Br J Cancer. 2008 Aug 19;99(4):584-90
references: 18665164
references: Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:27-35
references: 16897969
references: World J Gastroenterol. 2009 Jun 14;15(22):2689-92
references: 19522017
references: Oncology. 2000 Apr;58(3):191-7
references: 10765119
references: Ann Oncol. 2009 Apr;20(4):666-73
references: 19153121
references: Anticancer Res. 2001 May-Jun;21(3B):1705-12
references: 11497250
references: J Clin Oncol. 2008 Mar 20;26(9):1435-42
references: 18349393
references: Lancet Oncol. 2009 Nov;10 (11):1063-9
references: 19818685
references: Ann Oncol. 1997 Feb;8(2):163-8
references: 9093725